HK210196A - Human manganese superoxide dismutase and methods of treatment - Google Patents

Human manganese superoxide dismutase and methods of treatment

Info

Publication number
HK210196A
HK210196A HK210196A HK210196A HK210196A HK 210196 A HK210196 A HK 210196A HK 210196 A HK210196 A HK 210196A HK 210196 A HK210196 A HK 210196A HK 210196 A HK210196 A HK 210196A
Authority
HK
Hong Kong
Prior art keywords
superoxide dismutase
manganese superoxide
human manganese
treatment
methods
Prior art date
Application number
HK210196A
Other languages
English (en)
Inventor
Jacob R Hartman
Yaffa Beck
Abraham Nimrod
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Publication of HK210196A publication Critical patent/HK210196A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK210196A 1987-03-27 1996-11-28 Human manganese superoxide dismutase and methods of treatment HK210196A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3273487A 1987-03-27 1987-03-27
US16111788A 1988-02-26 1988-02-26

Publications (1)

Publication Number Publication Date
HK210196A true HK210196A (en) 1996-12-06

Family

ID=26708809

Family Applications (1)

Application Number Title Priority Date Filing Date
HK210196A HK210196A (en) 1987-03-27 1996-11-28 Human manganese superoxide dismutase and methods of treatment

Country Status (8)

Country Link
EP (2) EP0284105B1 (de)
JP (2) JP3013896B2 (de)
AT (1) ATE130196T1 (de)
CA (1) CA1339299C (de)
DE (1) DE3854678T2 (de)
GR (1) GR3018728T3 (de)
HK (1) HK210196A (de)
IL (1) IL85876A (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326003B1 (en) 1986-10-14 2001-12-04 Chiron Corporation Manganese superoxide dismutase cloning and expression in microorganisms
US5260204A (en) * 1987-03-14 1993-11-09 Boehringer Ingelheim International Gmbh Human manganese superoxide dismutase (hMn-SOD)
EP0676472A1 (de) * 1987-03-14 1995-10-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Humane Mangan-Superoxiddismutase (hMn-SOD)
JPH0780784B2 (ja) * 1987-10-23 1995-08-30 宇部興産株式会社 微小循環障害に基づく心筋虚血傷害治療薬
JPH01233228A (ja) * 1988-03-11 1989-09-19 Toyo Jozo Co Ltd 悪性腫瘍細胞転移防止剤
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
DK0587055T3 (da) * 1992-09-09 2002-04-02 Bio Technology General Corp Anvendelse af mangan-superoxiddismutase (Mn-SOD) til fremstilling af lægemidler til behandling af sygdomme i lav dosering
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
AU5717094A (en) * 1992-12-28 1994-07-19 Sii Technoresearch, Inc. Human variant manganese superoxide dismutase
IL109112A0 (en) * 1993-03-24 1994-06-24 Boehringer Ingelheim Pharma Pharmaceutical compositions containing human manganese superoxide dismutase
US6887856B1 (en) * 1993-10-15 2005-05-03 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
US5985633A (en) * 1997-09-10 1999-11-16 University Of Florida Human manganese superoxide dismutase proteins
AU2001255226A1 (en) * 2000-03-31 2001-10-15 University Of Southern California Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
CN101955918B (zh) * 2009-07-17 2014-05-21 华东理工大学 一种生产重组高活性锰超氧化物歧化酶的方法
US9976127B2 (en) 2013-11-04 2018-05-22 Aldo Mancini Manganese superoxide dismutase variants and uses thereof
ITRM20130608A1 (it) * 2013-11-04 2015-05-05 Aldo Mancini Manganese superossido dismutasi ricombinante e usi di essa
CN107427433B (zh) 2015-04-18 2020-10-20 捷鸥化妆品株式会社 酪氨酸酶活性抑制剂及皮肤外用剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5816685A (ja) * 1981-07-22 1983-01-31 Takeda Chem Ind Ltd 固定化酵素，その製造法および製剤
JPS5886098A (ja) * 1981-11-17 1983-05-23 Mamoru Sugiura マンガン−ス−パ−オキシドデイスムタ−ゼ測定用試薬
EP0656418B1 (de) * 1983-10-03 2002-12-04 Chiron Corporation Klonieren von Superoxiddismutase und Expression in Mikroorganismen
ATE63757T1 (de) * 1985-03-28 1991-06-15 Chiron Corp Expression durch verwendung von fusionsgenen fuer proteinproduktion.
EP0213628A3 (de) * 1985-09-03 1988-09-21 Yeda Research And Development Company, Ltd. Expression von Superoxiddismutase in eukaryotischen Zellen
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
IE59498B1 (en) * 1985-11-22 1994-03-09 Bio Technology General Corp Human manganese superoxide dismutase analog, plasmid for its expression and method of recovering it in enzymatically active form
EP0676472A1 (de) * 1987-03-14 1995-10-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Humane Mangan-Superoxiddismutase (hMn-SOD)

Also Published As

Publication number Publication date
DE3854678D1 (de) 1995-12-21
EP0691401A1 (de) 1996-01-10
JPS6427470A (en) 1989-01-30
EP0284105A3 (en) 1989-01-25
EP0284105B1 (de) 1995-11-15
CA1339299C (en) 1997-08-19
GR3018728T3 (en) 1996-04-30
IL85876A (en) 2001-11-25
JP3013896B2 (ja) 2000-02-28
EP0284105A2 (de) 1988-09-28
DE3854678T2 (de) 1996-06-13
JPH08317789A (ja) 1996-12-03
ATE130196T1 (de) 1995-12-15
IL85876A0 (en) 1988-09-30

Similar Documents

Publication Publication Date Title
GR3018728T3 (en) Human manganese superoxide dismutase and methods of treatment.
BG101028A (en) Synthetic peptide analogs of lung surfactant protein sp-c
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
ES8600060A1 (es) Procedimiento para preparar un medicamento envasado que contiene como sustancia activa un antagonista del calcio tal como nifedipina, verapamil diltiazem y otros.
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
IL86633A (en) 2-furanone derivatives, their preparation and pharmaceutical compositions containing them
NZ258019A (en) Medicinal compositions containing potassium, zinc, calcium and rubidium ions having the same properties as oak bark extract
AU6174490A (en) Methods and compositions; purified preparation of neural progenitor regulatory factor
EP1127577A3 (de) Ligand für den c-Kit-Rezepten und Verfahren zu seiner Nutzung
ES429585A1 (es) Procedimiento de preparacion de un alcanol superior.
IL115966A (en) Neuroprotective pharmaceutical compositions comprising GDNF
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
AU5323396A (en) Methods of treating inflammation and compositions therefor
IL69475A (en) Polypeptide having an action on the immunological system,processes for its isolation and purification,its protease cleavage products and pharmaceutical compositions containing them
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
DE69213935D1 (en) Neue heterocyclische carbonsäuren
NZ326345A (en) Composition containing diosgenin
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
AU631649B2 (en) Polypeptide pharmaceutical composition
UA42722C2 (uk) Сульфіди, сульфоксиди або сульфони, або їх фармацевтично прийнятні солі і фармацевтична композиція, що їх містить
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
YU40398A (sh) Kompozicija nazalnog spreja za davanje sredstva za lečenje odloženog napada emezisa
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
UA27055C2 (uk) Лікарський препарат імуhозаміhhої дії hа осhові клітиhhої суспеhзії та спосіб лікуваhhя сиhдрому hабутого імуhодефіциту (віл-іhфекції) з використаhhям цього препарату

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)